Wedbush Reiterates an 'Underperform' on Dendreon (DNDN); Sells Victrelis Royalty for $125M, Delaying Inevitable Financing
Go back to Wedbush Reiterates an 'Underperform' on Dendreon (DNDN); Sells Victrelis Royalty for $125M, Delaying Inevitable Financing| Dendreon Corp (NASDAQ: DNDN) | Delayed: 0.13 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $0.13 | 52 Week High | $3.46 | |||
| Open | $11.75 | 52 Week Low | $0.11 | |||
| Day High | $0.13 | P/E | N/A | |||
| Day Low | $0.13 | EPS | $-1.63 | |||
| Volume | 279 | |||||
| Merck & Co. (NYSE: MRK) | Delayed: 135.84 +0.29 (0.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $135.55 | 52 Week High | $65.46 | |||
| Open | $134.43 | 52 Week Low | $47.97 | |||
| Day High | $135.97 | P/E | 92.41 | |||
| Day Low | $133.40 | EPS | $1.47 | |||
| Volume | 6,868,318 | |||||
